Key Points
- Venrock Healthcare Capital Par purchased 9,004 Lycia Therapeutics shares at an average price of $26.28, investing $236,625 and increasing its stake by 0.13%.
- Following the transaction, Venrock directly owned 6,850,237 shares valued at approximately $180 million. The investor also made several recent purchases, including 1.95 million shares bought for $35.2 million on October 26.
- Lycia Therapeutics shares opened at $26.40, compared with a 52-week range of $22.19 to $36.49. The biotechnology company develops LYTAC medicines designed to direct disease-causing extracellular and cell-surface proteins for cellular degradation.
Lycia Therapeutics, Inc. (NASDAQ:LYCA - Get Free Report) major shareholder Venrock Healthcare Capital Par bought 1,000 shares of the company's stock in a transaction dated Thursday, October 29th. The shares were purchased at an average price of $26.33 per share, with a total value of $26,330.00. Following the completion of the acquisition, the insider owned 6,841,233 shares of the company's stock, valued at $180,129,664.89. This trade represents a 0.01% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Friday, October 30th, Venrock Healthcare Capital Par bought 9,004 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $26.28 per share, for a total transaction of $236,625.12.
- On Wednesday, October 28th, Venrock Healthcare Capital Par bought 15,000 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $25.45 per share, for a total transaction of $381,750.00.
- On Tuesday, October 27th, Venrock Healthcare Capital Par purchased 39,796 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $26.62 per share, for a total transaction of $1,059,369.52.
- On Monday, October 26th, Venrock Healthcare Capital Par purchased 1,952,705 shares of Lycia Therapeutics stock. The shares were acquired at an average cost of $18.04 per share, with a total value of $35,226,798.20.
- On Friday, October 23rd, Venrock Healthcare Capital Par bought 52,939 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $25.91 per share, with a total value of $1,371,649.49.
Lycia Therapeutics Trading Down 4.8%
Shares of NASDAQ LYCA opened at $26.40 on Friday. Lycia Therapeutics, Inc. has a 12 month low of $22.19 and a 12 month high of $36.49.
Lycia Therapeutics Company Profile
(
Get Free Report)
Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company's approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.
Lycia's technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
